Public Advisory - Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled because it may contain particulate matter
OTTAWA, ON, Aug. 9, 2022 /CNW/ -
Summary
Product: Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100)
Issue: Health product ? product quality
What to do: Check your product or contact your pharmacist to determine if it is recalled. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal. If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
Who this is for: General public
Affected products
Product
DIN
Lot
Expiry date
Taro Zoledronic acid injection 5mg/100mL
02415100
JKX1910A
JKX4318A
JKX5541A
HAC2371A
HAC4421A
HAD0156A
April-2023
Aug-2023
Nov-2023
Jun-2024
Nov-2024
Jan-2025
Issue Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.
Zoledronic acid is a prescription drug used to treat and prevent osteoporosis and to treat Paget's disease (a condition that disrupts the normal cycle of bone renewal).
If particulate matter is injected into a patient, there is potential for injury, such as inflammation or irritation of the veins, infections at the site of injection or in other parts of the body, allergic reactions, and the formation of blood clots that can move to other parts of the body. In the most serious cases, blood clots could move to the lungs and cause lung damage (pulmonary embolism), which can be permanent or fatal. Patients who have been treated with a recalled drug should go to the hospital immediately if they develop difficulty breathing, chest pain or confusion.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check your product or contact your pharmacist to determine if it is affected. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal.
If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
Contact Taro Pharmaceuticals Inc. by calling toll free at 1-800-268-1975 if you have questions about this recall.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...